International Journal of Reproductive BioMedicine

Published date: Apr 26 2025

Journal Title: International Journal of Reproductive BioMedicine

Issue title: International Journal of Reproductive BioMedicine (IJRM): Volume 23, Issue No. 2

Pages: 131 – 140

DOI: 10.18502/ijrm.v23i2.18482

Sara MohamedDepartment of Neonatology, Baylor Scott & White Health, Temple, Texas

Waverly KundysekTexas A&M University School of Medicine, College Station, Texas

Niraj VoraDepartment of Neonatology, Baylor Scott & White Health, Temple, Texas

Vinayak GovandeDepartment of Neonatology, Baylor Scott & White Health, Temple, Texas

Raza BajwaDepartment of Neonatology, Baylor Scott & White Health, Temple, Texas

Mohammad Nasir Uddinmohammad.uddin1@bswhealth.orgDepartment of Neonatology, Baylor Scott & White Health, Temple, Texas

Of all pregnant women in the United States an average of 1.5% reported to have type 1 or type 2 diabetes mellitus. Our review article will discuss and explore the relationship between pre-pregnancy diabetes and its adverse outcomes in mothers and neonates. Diabetes in pregnancy can cause a myriad of complications, many of which are related to microvascular changes, including diabetic nephropathy and retinopathy associated with preterm delivery, cesarean sections, and intrauterine growth restriction. Pregnant patients with diabetes also have an increased risk of pre-eclampsia, likely due to complications related to abnormal structure and function of the placenta. In addition, cardiovascular complications are more common and may present antepartum, intrapartum, or postpartum. Adverse neonatal outcomes that have been observed in diabetic pregnancies include fetal stillbirth and perinatal death, macrosomia, congenital malformations, respiratory distress, and neurological impairments. These complications explain the increased morbidity and mortality rate of infants of diabetic mothers, and the increased frequency of neonatal intensive care unit hospitalizations after birth. Diabetes in pregnancy causes a spectrum of changes in the maternal-fetal interface. This review addresses the placental changes during pregnancy and its adverse maternal and neonatal outcomes. We strongly believe the material discussed in this article can help in understanding the effects of diabetes during pregnancy which will ultimately aid in designing interventions to prevent these adverse outcomes.

Keywords: Diabetes mellitus, Pregnancy, Maternal health, Pre-eclampsia, Neonatal health

[1] Kitzmiller JL, Ferrara A, Peng T, Cissell MA, Kim C, Cowie CC, et al. Preexisting diabetes and pregnancy. 3rd Ed. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases (US); 2018.

[2] Uddin MN, Beeram MR, Kuehl TJ. Diabetes mellitus and preeclampsia. Med J Obstet Gynecol 2013; 1: 1016.

[3] Harris LK, Keogh RJ, Wareing M, Baker PN, Cartwright JE, Aplin JD, et al. Invasive trophoblasts stimulate vascular smooth muscle cell apoptosis by a fas ligand-dependent mechanism. Am J Pathol 2006; 169: 1863–1874.

[4] Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature 2001; 410: 37–40.

[5] Garrington TP, Johnson GL. Organization and regulation of mitogen-activated protein kinase signaling pathways. Curr Opin Cell Biol 1999; 11: 211–218.

[6] Kolch W. Meaningful relationships: The regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J 2000; 351: 289–305.

[7] Kyriakis JM, Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 2001; 81: 807–869.

[8] Nebreda AR, Porras A. p38 MAP kinases: Beyond the stress response. Trends Biochem Sci 2000; 25: 257–260.

[9] Uddin MN, Horvat D, Glaser SS, Mitchell BM, Puschett JB. Examination of the cellular mechanisms by which marinobufagenin inhibits cytotrophoblast function. J Biol Chem 2008; 283: 17946–17953.

[10] Barak Y, Nelson MC, Ong ES, Jones YZ, Ruiz-Lozano P, Chien KR, et al. PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol Cell 1999; 4: 585–595.

[11] Keelan JA, Sato TA, Marvin KW, Lander J, Gilmour RS, Mitchell MD. 15-deoxy-delta(12,14)-prostalandin J(2), a ligand for peroxisome proliferator-activated receptor-gamma, induces apoptosis in JEG3 choriocarcinoma cells. Biochem Biophys Res Commun 1999; 262: 579–585.

[12] Schaiff WT, Carlson MG, Smith SD, Levy R, Nelson DM, Sadovsky Y. Peroxisome proliferator-activated receptor-gamma modulates differentiation of human trophoblast in a ligand-specific manner. J Clin Endocrinol Metab 2000; 85: 3874–3881.

[13] Cawyer CR, Horvat D, Leonard D, Allen SR, Jones RO, Zawieja DC, et al. Hyperglycemia impairs cytotrophoblast function via stress signaling. Am J Obstet Gynecol 2014; 211: 541. e1-e8.

[14] Athanassiades A, Hamilton GS, Lala PK. Vascular endothelial growth factor stimulates proliferation but not migration or invasiveness in human extravillou trophoblast. Biol Reprod 1998; 59: 643–654.

[15] Torry DS, Hinrichs M, Torry RJ. Determinants of placental vascularity. Am J Reprod Immunol 2004; 51: 257–268.

[16] Venkatesha S, Toporsian M, Lam C, Hanai JI, Mammoto T, Kim YM, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006; 12: 642–649.

[17] Crocker IP, Strachan BK, Lash GE, Cooper S, Warren AY, Baker PN. Vascular endothelial growth factor but not placental growth factor promotes trophoblast syncytialization in vitro. J Soc Gynecol Investig 2001; 8: 341–346.

[18] Maglione D, Guerriero V, Viglietto G, Ferraro MG, Aprelikova O, Alitalo K, et al. Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PlGF), are transcribed from a single gene of chromosome 14. Oncogene 1993; 8: 925–931.

[19] Kitzmiller JL, Combs CA. Diabetic nephropathy and pregnancy. Obstet Gynecol Clin North Am 1996; 23: 173–203.

[20] Gregory R, Scott AR, Mohajer M, Tattersall RB. Diabetic pregnancy 1977–1990: Have we reached a plateau? J R Coll Physicians Lond 1992; 26: 162–166.

[21] Miodovnik M, Rosenn BM, Khoury JC, Grigsby JL, Siddiqi TA. Does pregnancy increase the risk for development and progression of diabetic nephropathy? Am J Obstet Gynecol 1996; 174: 1180–1191.

[22] Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, Lloyd-Jones DM, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women-2011 update: A Guideline from the American Heart Association. Circulation 2011; 123: 1243–1262.

[23] Colstrup M, Mathiesen ER, Damm P, Jensen DM, Ringholm L. Pregnancy in women with type 1 diabetes: Have the goals of St. Vincent declaration been met concerning foetal and neonatal complications? J Matern Fetal Neonatal Med 2013; 26: 1682–1686.

[24] Macintosh MCM, Fleming KM, Bailey JA, Doyle P, Modder J, Acolet D, et al. Perinatal mortality and congenital anomalies in babies of women with type 1 or type 2 diabetes in England, Wales, and Northern Ireland: Population based study. BMJ 2006; 333: 177.

[25] Anderson UD, Olsson MG, Kristensen KH, Åkerström B, Hansson SR. Review: Biochemical markers to predict preeclampsia. Placenta 2012; 33 (Suppl.): S42–47.

[26] Pridjian G, Puschett JB. Preeclampsia. Part 1: Clinical and pathophysiologic considerations. Obstet Gynecol Surv 2002; 57: 598–618.

[27] Yu Y, Jenkins AJ, Nankervis AJ, Hanssen KF, Scholz H, Henriksen T, et al. Anti-angiogenic factors and pre-eclampsia in type 1 diabetic women. Diabetologia 2009; 52: 160–168.

[28] Combs CA, Rosenn B, Kitzmiller JL, Khoury JC, Wheeler BC, Miodovnik M. Early-pregnancy proteinuria in diabetes related to preeclampsia. Obstet Gynecol 1993; 82: 802–807.

[29] Caufriez A, Frankenne F, Hennen G, Copinschi G. Regulation of maternal IGF-I by placental GH in normal and abnormal human pregnancies. Am J Physiol 1993; 265: E572–577.

[30] Yu Y, Luo GH, Zhang J, Jiang H, Wei J, Shi YP, et al. Increased mRNA levels of apolipoprotein M and apolipoprotein AI in the placental tissues with fetal macrosomia. Arch Gynecol Obstet 2015; 291: 299–303.

[31] Kc K, Shakya S, Zhang H. Gestational diabetes mellitus and macrosomia: A literature review. Ann Nutr Metab 2015; 66 (Suppl.): 14–20.

[32] Lazer S, Biale Y, Mazor M, Lewenthal H, Insler V. Complications associated with the macrosomic fetus. Journal of Reproductive Medicine 1986; 31: 501–505.

[33] Evers IM, De Valk HW, Visser GHA. Risk of complications of pregnancy in women with type 1 diabetes: Nationwide prospective study in the Netherlands. BMJ 2004; 328: 915.

[34] Landon MB, Gabbe SG. Diabetes and pregnancy. Med Clin North Am 1988; 72: 1493–1511.

[35] Kitzmiller JL, Brown ER, Phillippe M, Stark AR, Acker D, Kaldany A, et al. Diabetic nephropathy and perinatal outcome. Am J Obstet Gynecol 1981; 141: 741–751.

[36] Marvin KW, Eykholt RL, Keelan JA, Sato TA, Mitchell MD. The 15-deoxy-delta(12,14)-prostaglandin J(2)receptor, peroxisome proliferator activated receptor-gamma (PPARgamma) is expressed in human gestational tissues and is functionally active in JEG3 choriocarcinoma cells. Placenta 2000; 21: 436–440.

[37] Piper JM, Xenakis EM, Langer O. Delayed appearance of pulmonary maturation markers is associated with poor glucose control in diabetic pregnancies. J Matern-Fetal Med 1998; 7: 148–153.

[38] McGillick EV, Morrison JL, McMillen IC, Orgeig S. Intrafetal glucose infusion alters glucocorticoid signaling and reduces surfactant protein mRNA expression in the lung of the late-gestation sheep fetus. Am J Physiol Regul Integr Comp Physiol 2014; 307: R538–545.

[39] Miakotina OL, Goss KL, Snyder JM. Insulin utilizes the PI 3-kinase pathway to inhibit SP-A gene expression in lung epithelial cells. Respir Res 2002; 3: 27.

[40] Pinchefsky EF, Hahn CD, Kamino D, Chau V, Brant R, Moore AM, et al. Hyperglycemia and glucose variability are associated with worse brain function and seizures in neonatal encephalopathy: A prospective cohort study. J Pediatr 2019; 209: 23–32.

[41] Kramer CK, Campbell S, Retnakaran R. Gestational diabetes and the risk of cardiovascular disease in women: A systematic review and meta-analysis. Diabetologia 2019; 62: 905–914.

[42] Shand AW, Bell JC, McElduff A, Morris J, Roberts CL. Outcomes of pregnancies in women with pre-gestational diabetes mellitus and gestational diabetes mellitus: A population-based study in New South Wales, Australia, 1998–2002. Diabet Med 2008; 25: 708–715.

[43] Odar E, Wandabwa J, Kiondo P. Maternal and fetal outcome of gestational diabetes mellitus in Mulago hospital, Uganda. Afr Health Sci 2004; 4: 9–14.

[44] Seghieri G, Anichini R, De Bellis A, Alviggi L, Franconi F, Breschi MC. Relationship between gestational diabetes mellitus and low maternal birth weight. Diabetes Care 2002; 25: 1761–1765.

[45] Wang M, Athayde N, Padmanabhan S, Cheung NW. Causes of stillbirths in diabetic and gestational diabetes pregnancies at a NSW tertiary referral hospital. Aust N Z J Obstet Gynaecol 2019; 59: 561–566.

[46] Dudley DJ. Diabetic-associated stillbirth: Incidence, pathophysiology, and prevention. Clin Perinatol 2007; 34: 611–626.

[47] Usta A, Usta CS, Yildiz A, Ozcaglayan R, Sen Dalkiran E, Savkli A, et al. Frequency of fetal macrosomia and the associated risk factors in pregnancies without gestational diabetes mellitus. Pan Afr Med J 2017; 26: 62.

[48] Vambergue A, Fajardy I. Consequences of gestational and pregestational diabetes on placental function and birth weight. World J Diabetes 2011; 2: 196–203.

[49] Kampmann U, Knorr S, Fuglsang J, Ovesen P. Determinants of maternal insulin resistance during pregnancy: An updated overview. J Diabetes Res 2019; 2019: 5320156.

[50] Velegrakis A, Sfakiotaki M, Sifakis S. Human placental growth hormone in normal and abnormal fetal growth. Biomed Rep 2017; 7: 115–122.

[51] Fuglsang J, Lauszus F, Ørskov H, Ovesen P. Placental growth hormone during pregnancy in a growth hormone deficient woman with type 1 diabetes compared to a matching diabetic control group. Growth Horm IGF Res 2004; 14: 66–70.

[52] Hubbard EM, Hay Jr WW. The term newborn: Hypoglycemia. Clin Perinatol 2021; 48: 665–679.

[53] Tam EWY, Haeusslein LA, Bonifacio SL, Glass HC, Rogers EE, Jeremy RJ, et al. Hypoglycemia is associated with increased risk for brain injury and adverse neurodevelopmental outcome in neonates at risk for encephalopathy. J Pediatr 2012; 161: 88–93.

[54] Perna R, Loughan AR, Le J, Tyson K. Gestational diabetes: Long-term central nervous system developmental and cognitive sequelae. Appl Neuropsychol Child 2015; 4: 217–220.

[55] Van Lieshout RJ, Voruganti LP. Diabetes mellitus during pregnancy and increased risk of schizophrenia in offspring: A review of the evidence and putative mechanisms. J Psychiatry Neurosci 2008; 33: 395–404.

[56] Li M, Fallin MD, Riley A, Landa R, Walker SO, Silverstein M, et al. The association of maternal obesity and diabetes with autism and other developmental disabilities. Pediatrics 2016; 137: e20152206.